Adalimumab is a recombinant human IgG1 mono-clonal antibody to TNF-a that specifically blocks receptor binding of TNF-a (but not TNF-b); it also lyses cells expressing TNF-a on their surface in the presence of complement proteins. Adalimumab is currently FDA approved for use in patients with RA, PsA, and AS as a 40 mg dose SC every other week. It may be used in combination with glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, methotrexate or other DMARDs. In addition, an increased dosing frequency of 40 mg SC every week is on label for RA patients not receiving methotrexate in combination with adalimu-mab (package insert for Humira, 2006).
Copyright © 2018-2021 BrainKart.com; All Rights Reserved. (BS) Developed by Therithal info, Chennai.